You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,845,505


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,845,505
Title:Prediction of therapeutic response in inflammatory conditions
Abstract: Response to treatment of an inflammatory condition can be predicted based on characteristics of one or more markers from a subject. The markers can include expressions of nucleotide sequences identified herein and of combinations thereof. A response value can be calculated based on characteristics (e.g., expression levels) of one or more of the markers, as well as other characteristics of the subject, such as baseline clinical data. The treatment can be administered when the response value is beyond a threshold.
Inventor(s): Lilley; Patrick (Aliso Viejo, CA), Nunez; Matthew (Newport Beach, CA)
Assignee: BLUEPRINT BIO, INC. (Aliso Viejo, CA)
Application Number:15/011,059
Patent Claims:1. A method of treatment, comprising: measurinq, from a sample of a subject prior to administration of a TNF inhibitor treatment to the subject, (a) an amount of an mRNA sequence corresponding to SEQ ID NO:1, present in the sample; and (b) an amount of an mRNA sequence comprising SEQ ID NO:2, present in the sample; diagnosing the subject as a responsive subject when the subject, prior to administration of the TNF inhibitor treatment, has a response value substantially equivalent to the final r[00] calculated in the sequence of operations below and beyond a threshold: 1 r[02]=ADD(r[5], 2) 2 r[00]=ADD(r[6], 1) 3 r[00]=DIV(r[2], r[0]) 4 r[01]=SIN(r[6]) 5 r[00]=SUB(r[0], r[1]) 6 r[02]=MOD(r[1], r[0]) 7 r[03]=MOD(5, r[0]) 8 r[00]=SIN(r[0]) 9 r[00]=ADD(r[2], r[0]) 10 r[03]=MUL(r[3], r[3]) 11 r[02]=ADD(r[6], r[3]) 12 r[03]=DIV(r[3], r[2]) 13 r[00]=ADD(r[3], r[0]) 14 r[00]=ADD(r[3], r[0]) wherein: r[5] is a normalized value of the amount of the mRNA sequence corresponding to SEQ ID NO:1; and r[6] is a normalized value of the amount of the mRNA sequence corresponding to SEQ ID NO:2; and after the diagnosing, administering to the responsive subject the TNF inhibitor treatment, comprising administration of an effective amount of a medicament comprising a TNF inhibitor.

2. The method of claim 1, wherein after the administering, the responsive subject has a decrease in a DAS28 score.

3. The method of claim 1, further comprising: not administering the medicament to the subject, within one month of the diagnosing, when the response value is not beyond the threshold.

4. The method of claim 1, wherein the medicament comprises infliximab, adalimumab, leflunomide, anakinra, azathioprine, cyclophosphamide, and/or etanercept.

5. The method of claim 1, wherein the medicament comprises an anti-inflammatory agent.

6. The method of claim 1, wherein the medicament comprises a monoclonal antibody.

7. The method of claim 1, wherein the responsive subject has a decrease in DAS28 score within a 14 week period after administering the medicament.

8. The method of claim 1, wherein the responsive subject has a decrease in DAS28 score by 1.2 or more within a 14 week period after commencing administering the medicament.

9. The method of claim 1, wherein the threshold is 0 or a value between a first value and a second value, wherein the first value is a mean of sample response values of a first one or more sample subjects who respond to an anti-TNF treatment, and the second value is a mean of sample response values of a second one or more subjects who do not respond to the anti-TNF treatment, and wherein the sample response values for each of the sample subjects is determined based on the amount of an mRNA sequence corresponding to SEQ ID NO:1, present in the sample; and the amount of an mRNA sequence comprising SEQ ID NO:2, present in the sample.

10. A method of treatment, comprising: measuring, from a sample of a subject prior to administration of a TNF inhibitor treatment to the subject, (a) an amount of an mRNA sequence corresponding to SEQ ID NO:1, present in the sample; and (b) an amount of an mRNA sequence comprising SEQ ID NO:2, present in the sample; diagnosing the subject to be a responsive subject when the subject, prior to administration of the TNF inhibitor treatment to the subject, has a response value substantially equivalent to the final r[00] calculated in the sequence of operations below and beyond a threshold: 1 r[06]=MUL(r[12], 2) 2 r[07]=MUL(r[14], 7) 3 r[07]=SUB(11, r[7]) 4 r[06]=SUB(r[6], r[7]) 5 r[00]=DIV(5, r[6]) 6 r[05]=SUB(r[14], r[7]) 7 r[02]=DIV(r[13], r[5]) 8 r[07]=SUB(r[13], r[7]) 9 r[00]=ADD(r[2], r[0]) 10 r[05]=SUB(r[14], r[7]) 11 r[02]=DIV(2, r[5]) 12 r[00]=ADD(r[2], r[0]) wherein: r[12]=Treatment_num, wherein Treatment_num=1 if the subject is administered a drug, Treatment_num=0 if the subject is administered a placebo; r[14] is a normalized value of the amount of the mRNA sequence corresponding to SEQ ID NO:1); r[13] is a normalized value of the amount of the mRNA sequence corresponding to SEQ ID NO:2; and after the diagnosing, administering to the responsive subject the TNF inhibitor treatment, comprising administration of an effective amount of a medicament comprising a TNF inhibitor.

11. A method of treatment, comprising: measuring, from a sample of a subject prior to a TNF inhibitor treatment, (a) an amount of an mRNA sequence corresponding to SEQ ID NO:1, present in the sample; and (b) an amount of an mRNA sequence comprising SEQ ID NO:2, present in the sample; diagnosing the subject to be a responsive subject when the subject, prior to the TNF inhibitor treatment, has a response value substantially equivalent to the final r[00] calculated in the sequence of operations below and beyond a threshold: 1. r[03]=DIV(r[6], 5) 2. r[02]=MOD(7, r[3]) 3. r[01]=ADD(r[3], r[2]) 4. r[03]=SUB(r[6], r[2]) 5. r[02]=POW(r[6], r[1]) 6. r[03]=ADD(r[5], r[3]) 7. r[00]=MOD(r[3], r[2]) 8. r[00]=SUB(r[1], r[0]) wherein: r[6] is a normalized value of the amount of the mRNA sequence corresponding to SEQ ID NO:1; and r[5] is a normalized value of the amount of the mRNA sequence corresponding to SEQ ID NO:2; and administering to the responsive subject the TNF inhibitor treatment, wherein the TNF inhibitor treatment comprises administration to the responsive subject an effective amount of a medicament comprising a TNF inhibitor.

Details for Patent 9,845,505

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 08/24/1998 ⤷  Try a Trial 2039-02-26
Immunex Corporation ENBREL etanercept For Injection 103795 11/02/1998 ⤷  Try a Trial 2039-02-26
Immunex Corporation ENBREL etanercept For Injection 103795 05/27/1999 ⤷  Try a Trial 2039-02-26
Immunex Corporation ENBREL etanercept Injection 103795 09/27/2004 ⤷  Try a Trial 2039-02-26
Immunex Corporation ENBREL etanercept Injection 103795 02/01/2007 ⤷  Try a Trial 2039-02-26
Immunex Corporation ENBREL MINI etanercept Injection 103795 09/14/2017 ⤷  Try a Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.